DelveInsight’s, “Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Chronic Rhinosinusitis with Nasal Polyps pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Chronic Rhinosinusitis with Nasal Polyps research. Learn more about our innovative pipeline today! @ Chronic Rhinosinusitis with Nasal Polyps Pipeline Outlook
Key Takeaways from the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report
- In October 2024:- Johns Hopkins University- The overarching objective of this study is to determine the clinical effectiveness of dupilumab for the treatment of CRS that includes several potential disease endotypes with the exclusion of the nasal polyp cluster that has previously been determined. The additional information gained from secondary and exploratory outcomes will help provide important insight for applied research studies and may also provide practical guidance to clinicians on how to select patients for treatment.
- In October 2024:- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.- The main purpose is to evaluate the effect of 611 on a background of mometasone furoate nasal spray (MFNS) in reducing endoscopic nasal polyp score (NPS) and nasal congestion/obstruction score (NCS) severity in eligible patients with CRSwNP whose disease remains inadequately controlled despite daily treatment with intranasal corticosteroid (INCS) therapy in comparison to placebo
- In October 2024:- Insmed Incorporated- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps. The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
- In October 2024:- Sanofi- The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous lunsekimig in adult participants (aged 18 to 70 years, inclusive) with CRSwNP who are inadequately controlled on intranasal corticosteroid treatment. Participants with and without co-morbid asthma will be included in the study, and lung function will be assessed in both groups.
- DelveInsight’s Chronic Rhinosinusitis with Nasal Polyps pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Chronic Rhinosinusitis with Nasal Polyps treatment.
- The leading Chronic Rhinosinusitis with Nasal Polyps Companies such as Keymed Biosciences Co. Ltd, GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd, and others.
- Promising Chronic Rhinosinusitis with Nasal Polyps Therapies such as Tezepelumab, GR1802, SHR-1905, Lunsekimig, LY3650150, and others.
Stay informed about the cutting-edge advancements in Chronic Rhinosinusitis with Nasal Polyps treatments. Download for updates and be a part of the revolution in care @ Chronic Rhinosinusitis with Nasal Polyps Clinical Trials Assessment
Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs
- GSK3511294: GlaxoSmithKline
GSK3511294 (depemokimab) is a novel investigational treatment being studied for chronic rhinosinusitis with nasal polyps (CRSwNP). Depemokimab is thought to work by inhibiting interleukin-5 (IL-5), a key cytokine involved in the type 2 inflammatory response that drives eosinophilic inflammation in CRSwNP. Blocking IL-5 may help reduce polyp size and improve symptoms. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Chronic rhinosinusitis with nasal polyps.
- CM326: Keymed Biosciences Co. Ltd
CM326 is a monoclonal antibody being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The rationale for targeting thymic stromal lymphopoietin (TSLP) with CM326 is based on its role in the pathogenesis of CRSwNP. TSLP is a key cytokine involved in the initiation and maintenance of type 2 inflammatory responses, which are characteristic of CRSwNP. Currently, the drug is in the Phase II stage of development to treat Chronic rhinosinusitis with nasal polyps.
Learn more about Chronic Rhinosinusitis with Nasal Polyps Drugs opportunities in our groundbreaking Melanoma research and development projects @ Chronic Rhinosinusitis with Nasal Polyps Unmet Needs
Chronic Rhinosinusitis with Nasal Polyps Companies
Keymed Biosciences Co. Ltd, GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd, and others.
Chronic Rhinosinusitis with Nasal Polyps pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Chronic Rhinosinusitis with Nasal Polyps Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in Chronic Rhinosinusitis with Nasal Polyps treatment by visiting our website. Stay informed about how we’re transforming the future of Otolaryngology @ Chronic Rhinosinusitis with Nasal Polyps Market Drivers and Barriers, and Future Perspectives
Scope of the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report
- Coverage- Global
- Chronic Rhinosinusitis with Nasal Polyps Companies- Keymed Biosciences Co. Ltd, GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd, and others.
- Chronic Rhinosinusitis with Nasal Polyps Therapies- GR1802, SHR-1905, Lunsekimig, LY3650150, and others.
- Chronic Rhinosinusitis with Nasal Polyps Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Chronic Rhinosinusitis with Nasal Polyps Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Chronic Rhinosinusitis with Nasal Polyps Pipeline on our website @ Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Chronic Rhinosinusitis with Nasal Polyps: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Chronic Rhinosinusitis with Nasal Polyps – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- GSK3511294: GlaxoSmithKline
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- CM310: Keymed Biosciences
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Chronic Rhinosinusitis with Nasal Polyps Key Companies
- Chronic Rhinosinusitis with Nasal Polyps Key Products
- Chronic Rhinosinusitis with Nasal Polyps- Unmet Needs
- Chronic Rhinosinusitis with Nasal Polyps- Market Drivers and Barriers
- Chronic Rhinosinusitis with Nasal Polyps- Future Perspectives and Conclusion
- Chronic Rhinosinusitis with Nasal Polyps Analyst Views
- Chronic Rhinosinusitis with Nasal Polyps Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/